PMID- 22233979
OWN - NLM
STAT- MEDLINE
DCOM- 20120710
LR  - 20141120
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 27
IP  - 2
DP  - 2012 Mar
TI  - Cardiac resynchronization therapy: expanding clinical indications and refining 
      patient selection.
PG  - 137-42
LID - 10.1097/HCO.0b013e32834febd3 [doi]
AB  - PURPOSE OF REVIEW: Cardiac resynchronization therapy (CRT) can reduce morbidity 
      and mortality in patients with heart failure. However, a proportion of patients 
      do not respond to CRT. This review addresses important clinical questions 
      regarding patient selection for CRT. RECENT FINDINGS: Three recent large 
      randomized trials show that CRT reduces morbidity and mortality in patients with 
      New York Heart Association (NYHA) functional class II heart failure. 
      Observational studies and a recent meta-analysis suggest that patients with NYHA 
      III heart failure and atrial fibrillation may benefit from CRT. However, 
      atrioventricular node ablation should be considered in this population to ensure 
      greater than 92% biventricular pacing. Data from clinical trials do not support 
      the use of CRT in patients with baseline right bundle branch block (RBBB). 
      SUMMARY: Careful selection of CRT candidates is vital to improve patient outcomes 
      and reduce exposure to unnecessary complications. This review summarizes recent 
      data on the selection of CRT candidates, with emphasis on patients with NYHA I 
      and II heart failure, atrial fibrillation and RBBB.
FAU - Nery, Pablo B
AU  - Nery PB
AD  - University of Ottawa Heart Institute, Ottawa, Canada. Pnery@ottawa-heart.ca
FAU - Keren, Arieh
AU  - Keren A
FAU - Birnie, David H
AU  - Birnie DH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
SB  - IM
MH  - Cardiac Resynchronization Therapy/*methods
MH  - Global Health
MH  - Heart Conduction System/*physiopathology
MH  - *Heart Failure/mortality/physiopathology/therapy
MH  - Humans
MH  - Morbidity
MH  - *Patient Selection
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2012/01/12 06:00
MHDA- 2012/07/11 06:00
CRDT- 2012/01/12 06:00
PHST- 2012/01/12 06:00 [entrez]
PHST- 2012/01/12 06:00 [pubmed]
PHST- 2012/07/11 06:00 [medline]
AID - 10.1097/HCO.0b013e32834febd3 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2012 Mar;27(2):137-42. doi: 10.1097/HCO.0b013e32834febd3.